Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors (original) (raw)
References
Aeder SE, Martin PM, Soh JW, Hussaini IM (2004) PKC-η mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways. Oncogene 23:9062–9069 ArticlePubMedCAS Google Scholar
Basu A, Lazo JS (1992) Sensitization of human cervical carcinoma cells to _cis_-diamminedichloroplatinum (II) by bryostatin 1. Cancer Res 52:3119–3124 PubMedCAS Google Scholar
Corbett AH, Fernald AW, Osheroff N (1993) Protein kinase C modulates the catalytic activity of topoisomerase II by enhancing the rate of ATP hydrolysis: evidence for a common mechanism of regulation by phosphorylation. Biochemistry 32:2090–2097 ArticlePubMedCAS Google Scholar
Dale IL, Bradshaw TD, Gescher A, Pettit GR (1989) Comparison of effects of bryostatins 1 and 2 and 12–_O_-tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells. Cancer Res 49:3242–3245 PubMedCAS Google Scholar
El-Rayes BF, Gadgeel S, Shields AF, Manza S, Lorusso P, Philip PA (2006) Phase I study of bryostatin 1 and gemcitabine. Clin Cancer Res 12:7059–7062 ArticlePubMedCAS Google Scholar
Ford JM, Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42:155–199 PubMedCAS Google Scholar
Goodnight JE Jr, Moseley HS, Eilber FR, Sarna G, Morton DL (1979) _Cis_-dichlorodiammineplatinum (II) alone and combined with DTIC for treatment of disseminated malignant melanoma. Cancer Treat Rep 63:2005–2007 PubMed Google Scholar
Grunicke H, Hofmann J, Maly K, Goddard PM, Kelland LR, Morgan SE (1991) Enhancement of the antiproliferative effect of _cis_-diammine-dichloroplatinum (II) and other antitumor agents by inhibition of enzymes involved in growth factor signal transduction. In: Howell SB (ed) Platinum and other metal coordination compounds in cancer chemotherapy. Plenum Press, New York, pp 161–172 Google Scholar
Grunicke H, Hofmann J, Utz I, Uberall F (1994) Role of protein kinases in antitumor drug resistance. Ann Hematol 69:S1–S6 ArticlePubMedCAS Google Scholar
Grunicke HH, Uberall F (1992) Protein kinase C modulation. Semin Cancer Biol 3:351–360 PubMedCAS Google Scholar
Gschwendt M, Furstenberger G, Rose-John S, Rogers M, Kittstein W, Pettit GR, Herald CL, Marks F (1988) Bryostatin 1, an activator of protein kinase C, mimics as well as inhibits biological effects of the phorbol ester TPA in vivo and in vitro. Carcinogenesis 9:555–562 ArticlePubMedCAS Google Scholar
Gschwendt M, Leibersperger H, Kittstein W, Marks F (1992) Protein kinase C zeta and eta in murine epidermis. TPA induces down-regulation of PKC eta but not PKC zeta. FEBS Lett 307:151–155 ArticlePubMedCAS Google Scholar
Hallahan DE, Virudachalam S, Sherman ML, Huberman E, Kufe DW, Weichselbaum RR (1991) Tumor necrosis factor gene expression is mediated by protein kinase C following activation by ionizing radiation. Cancer Res 51:4565–4569 PubMedCAS Google Scholar
Hickman PF, Kemp GJ, Thompson CH, Salisbury AJ, Wade K, Harris AL, Radda GK (1995) Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic spectroscopic study. Br J Cancer 72:998–1003 PubMedCAS Google Scholar
Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ (1994) Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 12:553–559 PubMedCAS Google Scholar
Hofmann J, Doppler W, Jakob A, Maly K, Posch L, Uberall F, Grunicke HH (1988) Enhancement of the antiproliferative effect of _cis_-diamminedichloroplatinum (II) and nitrogen mustard by inhibitors of protein kinase C. Int J Cancer 42:382–388 ArticlePubMedCAS Google Scholar
Hornung RL, Pearson JW, Beckwith M, Longo DL (1992) Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res 52:101–107 PubMedCAS Google Scholar
Isonishi S, Andrews PA, Howell SB (1990) Increased sensitivity to _cis_-diamminedichloroplatinum (II) in human ovarian carcinoma cells in response to treatment with 12-_O_-tetradecanoylphorbol 13-acetate. J Biol Chem 265:3623–3627 PubMedCAS Google Scholar
Jackson DN, Foster DA (2004) The enigmatic protein kinase C delta: complex roles in cell proliferation and survival. FASEB J 18:627–636 ArticlePubMedCAS Google Scholar
Jayson GC, Crowther D, Prendiville J, McGown AT, Schneid C, Stern P, Young R, Brenchley P, Chang J, Owens S et al (1995) A Phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer 72:461–468 PubMedCAS Google Scholar
Liebes L, Potmesil M, Kim T, Pease D, Buckley M, Fry D, Cho J, Adler H, Dar K, Zeleniuch-Jacquotte A, Hochster H (1998) Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan. Clin Can Res 4:545–557 CAS Google Scholar
Masso-Welch PA, Winston JS, Edge S, Darcy KM, Asch H, Vaughan MM, Ip MM (2001) Altered expression and localization of PKC eta in human breast tumors. Breast Cancer Res Treat 68:211–223 ArticlePubMedCAS Google Scholar
Mohammad RM, Diwakaran H, Maki A, Emara MA, Pettit GR, Redman B, AL-Katib A (1995) Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leuk Res 19:667–673 ArticlePubMedCAS Google Scholar
Nezhat F, Wadler S, Muggia F, Mandeli J, Goldberg G, Rahaman J, Runowicz C, Murgo AJ, Gardner GJ (2004) Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study. Gynecol Oncol 93:144–148 ArticlePubMedCAS Google Scholar
Osada SI, Hashimoto Y, Nomura S, Kohno Y, Chida K, Tajima O, Kubo K, Akimoto K, Koizumi H, Kitamura Y, Suzuki K, Ohno S, Kuroki T (1993) Predominant expression of nPKCη, a Ca2+-independent isoform of protein kinase C in epithelial tissues, in association with epithelial differentiation. Cell Growth Diff 4:167–175 PubMedCAS Google Scholar
Perego P, Casati G, Gambetta RA, Soranzo C, Zunino F (1993) Effect of modulation of protein kinase C activity on cisplatin cytotoxicity in cisplatin-resistant and cisplatin-sensitive human osteosarcoma cells. Cancer Lett 72:53–58 ArticlePubMedCAS Google Scholar
Pettit GR, Herald CL, Doubek DL, Herald DL, Arnold E, Clardy J (1982) Isolation and structure of bryostatin 1. J Am Chem Soc 104:6846–6848 ArticleCAS Google Scholar
Philip PA, Harris AL (1995) Potential for protein kinase C inhibitors in cancer therapy. In: Muggia FM (ed) Concepts, mechanisms and new targets for chemotherapy, 1st edn. Kluwer, Boston, pp 3–28 Google Scholar
Philip PA, Rea D, Thavasu P, Carmichael J, Stuart NSA, Rockett H, Talbot DC, Ganesan T, Pettit GR, Balkwill F, Harris AL (1993) Phase I study of Bryostatin 1: assessment of interleukin 6 and tumor necrosis factor α induction in vivo. J Natl Cancer Inst 85:1812–1818 ArticlePubMedCAS Google Scholar
Pollack IF, Kawecki S, Lazo JS (1996) Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. J Neurosurg 84:1024–1032 ArticlePubMedCAS Google Scholar
Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Testa N, Stern P, McDermott R, Potter M, Pettit GR (1993) A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 68:418–424 PubMedCAS Google Scholar
Roberts JD, Smith MR, Feldman EJ, Cragg L, Millenson MM, Roboz GJ, Honeycutt C, Thune R, Padavic-Shaller K, Carter WH, Ramakrishnan V, Murgo AJ, Grant S (2006) Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin’s) lymphoma. Clin Cancer Res 12:5809–5816 ArticlePubMedCAS Google Scholar
Schuchter LM, Esa AH, May S, Laulis MK, Pettit GR, Hess AD (1991) Successful treatment of murine melanoma with bryostatin 1. Cancer Res 51:682–687 PubMedCAS Google Scholar
Szallasi Z, Du L, Levine R, Lewin NE, Nguyen PN, Williams MD, Pettit GR, Blumberg PM (1996) The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1. Cancer Res 56:2105–2111 PubMedCAS Google Scholar
Thompson CH, Macaulay VM, O’Byrne KJ, Kemp GJ, Wilner SM, Talbot DC, Harris AL, Radda GK (1996) Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply. Br J Cancer 73:1161–1165 PubMedCAS Google Scholar
Trenn G, Pettit GR, Takayama H, Hu-Li J, Sitkovsky MV (1988) Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins. J Immunol 140:433–439 PubMedCAS Google Scholar
Varterasian M, Eilender D, Mohammad R, Chen B, Hulburd K, Rodriguez D, Pluda J, Valdivieso M, Al-Katib A (1996) Phase I trial of bryostatin 1 in relapsed lymphoma and CLL. Proc Am Soc Clin Oncol 15:481 (Abstr # 1526) Google Scholar
Weitman S, Langevin AM, Berkow RL, Thomas PJ, Hurwitz CA, Kraft AS, Dubowy AL, Smith DL, Bernstein M (1999) A phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study. Clin Cancer Res 5:2344–2348 PubMedCAS Google Scholar
WHO (1979) Handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organization Offset Publication No. 48
Zhang R, Muller HJ, Kielassa K, Marks F, Gschwendt M (1994) Partial purification of a type eta protein kinase C from murine brain: separation from other protein kinase C isoenzymes and characterization. Biochem J 304:641–647 Google Scholar
Zhao M, Rudek MA, He P, Smith BD, Baker SD (2005) Validation and implementation of a method for determination of bryostatin 1 in human plasma by using liquid chromatography/tandem mass spectrometry. Anal Biochem 33:143–148 ArticleCAS Google Scholar